» Articles » PMID: 10052865

Vascular Nitric Oxide May Lessen Alzheimer's Risk

Overview
Journal Med Hypotheses
Specialty General Medicine
Date 1999 Mar 3
PMID 10052865
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Estrogen deficiency, hyperinsulinemia, type II diabetes, atherosclerosis, and a past history of elevated blood pressure may be associated with increased risk of Alzheimer's disease (AD). Common to all of these risk factors is a diminished capacity of vascular endothelium to generate nitric oxide (NO). Vascular NO has the potential to enhance the membrane polarization of cerebral neurons by increasing the open probability of calcium-activated potassium channels; this may protect neurons from the excessive calcium influx, potentiated by beta-amyloid peptides that is thought to mediate neuronal damage in AD. The possibility that NO/cyclic guanosine 3', 5'-phosphate (cGMP) may modulate the synthesis or processing of the amyloid precursor protein, also merits evaluation. Practical measures for promoting vascular NO production may include increased intakes of arginine, potassium, antioxidants, and fish-oil, as well as lifestyle measures that typically lower elevated blood pressure; potential benefits of chromium, glucosamine, and silicon should also be explored. In hypertensives, angiotensin-converting enzyme (ACE) inhibitors and sodium restriction may favorably influence endothelial function. Fish-oil should have the additional benefit of antagonizing the contribution of interleukin-1 to AD pathogenesis. Ancillary anti-excitotoxic measures such as magnesium, taurine, phenytoin, and vasodilators targeting ATP-dependent potassium (KATP) channels, may likewise reduce AD risk. Most of the nutritional measures suggested here would in any case be recommendable for preservation of vascular health.

Citing Articles

Cyrcadian Rhythm, Mood, and Temporal Patterns of Eating Chocolate: A Scoping Review of Physiology, Findings, and Future Directions.

Garbarino S, Garbarino E, Lanteri P Nutrients. 2022; 14(15).

PMID: 35956290 PMC: 9370573. DOI: 10.3390/nu14153113.


Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.

Manukhina E, Downey H, Shi X, Mallet R Exp Biol Med (Maywood). 2016; 241(12):1351-63.

PMID: 27190276 PMC: 4950272. DOI: 10.1177/1535370216649060.


Synaptic therapy in Alzheimer's disease: a CREB-centric approach.

Teich A, Nicholls R, Puzzo D, Fiorito J, Purgatorio R, Fa M Neurotherapeutics. 2015; 12(1):29-41.

PMID: 25575647 PMC: 4322064. DOI: 10.1007/s13311-014-0327-5.


Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion.

Won J, Kim J, Annamalai B, Shunmugavel A, Singh I, Singh A J Alzheimers Dis. 2012; 34(3):621-35.

PMID: 23254638 PMC: 4040220. DOI: 10.3233/JAD-121786.


The neuroprotective effects of cocoa flavanol and its influence on cognitive performance.

Nehlig A Br J Clin Pharmacol. 2012; 75(3):716-27.

PMID: 22775434 PMC: 3575938. DOI: 10.1111/j.1365-2125.2012.04378.x.